meprobamate has been researched along with Corneal Dystrophies in 1 studies
Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Neetens, A | 1 |
| Van Vlimmeren, H | 1 |
1 other study available for meprobamate and Corneal Dystrophies
| Article | Year |
|---|---|
Neurogenic etiology of corneal dystrophic diseases.
Topics: Adult; Corneal Dystrophies, Hereditary; Dexamethasone; Female; Humans; Male; Meprobamate; Middle Age | 1975 |